Febrile neutropenia is having a fever of ≥38.3 ºC or ≥38 ºC over an hour and neutropenia that is having an absolute neutrophil count (ANC) of <500 neutrophils/mm3 or an ANC <1000 neutrophils/mm3 expected to decline to ≤500 neutrophils/mm3 over the next 48 hours.
The risk of febrile neutropenia is directly proportional to the duration and severity of neutropenia.
Fever is frequently the only indication of infection in the neutropenic patient.
New drug applications approved by US FDA as of 1 - 15 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Imipenem-cilastatin exhibited better efficacy than piperacillin-tazobactam as empiric antibiotic for febrile neutropaenia in haematopoietic stem cell transplantation (HSCT) recipients, based on a study.
Empirical cefepime monotherapy is associated with less economic strain and lower risk of serious adverse or toxic effects of multidrug combinations compared with piperacillin-tazobactam in paediatric febrile neutropaenia patients, as shown in a study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Infectious Diseases - Malaysia digital copy today!
Results of a study show that a single diagnosed chlamydia infection is linked with increased risk of reproductive complications including pelvic inflammatory disease, ectopic pregnancy, and tubal factor infertility.
The US Food and Drug Administration (FDA) has approved tenofovir alafenamide (TAF), a nucleoside analog reverse transcriptase inhibitor, as a single agent for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.